RMTI

+ Watchlist + Portfolio

Rockwell Medical, Inc.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $8.57
52-Week Range: $4.89 – $12.90
Market Cap: $34.86M
P/E (TTM): —
EPS (TTM): -1.34
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.98
PEG Ratio: 4.43
Return on Equity: -15.53%
Return on Assets: -5.18%
Gross Margin: 17.71%
Operating Margin: -5.97%
Profit Margin: -7.33%
Current Ratio: 3.25
Debt/Equity: 0.40
Total Debt: $13.93M
Free Cash Flow: $350.38K
Revenue Growth: 10.60%
Earnings Growth: —
Enterprise Value: $24.00M

RMTI Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$72.81M	$83.61M	$101.49M	$69.26M
Cost of Revenue	$68.73M	$74.91M	$84.00M	$57.56M
Gross Profit	$4.08M	$8.70M	$17.48M	$11.70M
Research & Development	$3.12M	$1.11M	$19.00K	$0.00
Selling, General & Admin	$17.74M	$14.27M	$16.86M	$16.39M
Operating Expenses	$20.86M	$15.37M	$16.88M	$16.39M
Operating Income	-$16.78M	-$6.67M	$608.00K	-$4.69M
EBITDA	-$16.17M	-$4.69M	$2.95M	-$2.00M
Pretax Income	-$18.68M	-$8.44M	-$480.00K	-$5.31M
Net Income	-$18.68M	-$8.44M	-$480.00K	-$5.31M
Diluted EPS	-18.90	-3.70	-0.30	-1.50
Diluted Shares	986684	2.33M	3.11M	3.60M

RMTI Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$10.10M	$8.98M	$15.66M	$10.71M
Receivables	$6.26M	$10.90M	$8.29M	$8.14M
Inventory	$5.81M	$5.87M	$5.78M	$3.42M
Current Assets	$35.31M	$28.77M	$37.03M	$38.16M
Total Assets	$46.63M	$52.17M	$59.21M	$57.15M
Current Liabilities	$17.69M	$16.64M	$14.09M	$9.58M
Long-Term Debt	$7.55M	$8.29M	$8.47M	$8.83M
Total Liabilities	$32.53M	$30.88M	$26.62M	$20.16M
Retained Earnings	-$388.76M	-$397.20M	-$397.68M	-$402.99M
Shareholders' Equity	$14.11M	$21.29M	$32.59M	$36.98M
Working Capital	$17.62M	$12.13M	$22.94M	$28.58M

RMTI Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$16.93M	-$9.41M	$4.20M	-$659.00K
Capital Expenditure	-$281.00K	-$284.00K	-$1.01M	-$542.00K
Free Cash Flow	-$17.21M	-$9.70M	$3.19M	-$1.20M
Depreciation & Amortisation	$576.00K	$1.44M	$2.18M	$2.19M
Stock-Based Compensation	$315.00K	$932.00K	$1.29M	$1.82M
Investing Cash Flow	-$2.40M	-$3.04M	-$4.87M	-$8.54M
Financing Cash Flow	$16.15M	$11.34M	$7.35M	$4.25M
Share Repurchases	$0.00	—	—	—
Net Change in Cash	-$3.17M	-$1.11M	$6.68M	-$4.95M

RMTI Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$18.91M	$16.07M	$15.93M	$18.35M	$17.34M	$17.78M
Cost of Revenue	$15.87M	$13.57M	$13.65M	$14.47M	$14.44M	$14.54M
Gross Profit	$3.04M	$2.50M	$2.27M	$3.88M	$2.90M	$3.24M
Research & Development	$0.00	$0.00	$0.00	$0.00	—	$40.00K
Selling, General & Admin	$4.40M	$3.85M	$3.86M	$4.28M	$4.38M	$4.26M
Operating Expenses	$4.40M	$3.85M	$3.86M	$4.28M	$4.38M	$4.30M
Operating Income	-$1.36M	-$1.35M	-$1.58M	-$398.00K	-$1.48M	-$1.06M
EBITDA	-$699.00K	-$653.00K	-$924.00K	$278.00K	-$812.00K	-$399.00K
Pretax Income	-$1.51M	-$1.49M	-$1.75M	-$554.00K	-$1.60M	-$1.17M
Net Income	-$1.51M	-$1.49M	-$1.75M	-$554.00K	-$1.60M	-$1.17M
Diluted EPS	-0.40	-0.50	-0.50	-0.10	-0.40	-0.34
Diluted Shares	3.41M	3.43M	3.60M	3.94M	3.94M	3.96M

RMTI Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$11.39M	$12.48M	$13.61M	$10.71M	$9.61M	$10.52M
Receivables	$9.67M	$8.08M	$8.33M	$8.14M	$8.82M	$8.30M
Inventory	$5.04M	$4.16M	$3.96M	$3.42M	$3.06M	$2.82M
Current Assets	$33.03M	$31.61M	$37.51M	$38.16M	$36.94M	$36.36M
Total Assets	$53.96M	$52.63M	$57.49M	$57.15M	$57.42M	$56.53M
Current Liabilities	$11.21M	$10.95M	$9.58M	$9.58M	$9.87M	$11.17M
Long-Term Debt	$8.56M	$8.65M	$8.74M	$8.83M	$8.21M	$7.24M
Total Debt	$12.87M	$14.01M	$13.13M	$12.47M	$14.39M	$13.93M
Total Liabilities	$22.44M	$22.22M	$20.47M	$20.16M	$21.57M	$21.44M
Retained Earnings	-$399.19M	-$400.69M	-$402.44M	-$402.99M	-$404.60M	-$405.77M
Shareholders' Equity	$31.52M	$30.41M	$37.02M	$36.98M	$35.86M	$35.09M
Working Capital	$21.83M	$20.66M	$27.93M	$28.58M	$27.07M	$25.19M

RMTI Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$3.49M	$1.84M	-$1.31M	$2.29M	-$167.00K	$2.08M
Capital Expenditure	-$63.00K	-$164.00K	-$229.00K	-$86.00K	-$425.00K	-$617.00K
Free Cash Flow	-$3.55M	$1.68M	-$1.54M	$2.21M	-$592.00K	$1.46M
Depreciation & Amortisation	$539.00K	$563.00K	$544.00K	$546.00K	$511.00K	$492.00K
Stock-Based Compensation	$445.00K	$382.00K	$532.00K	$457.00K	$479.00K	$403.00K
Investing Cash Flow	-$1.00K	-$103.00K	-$4.31M	-$4.13M	-$122.00K	-$487.00K
Financing Cash Flow	-$783.00K	-$650.00K	$6.74M	-$1.06M	-$813.00K	-$683.00K
Net Change in Cash	-$4.27M	$1.09M	$1.13M	-$2.90M	-$1.10M	$910.00K

Market Snapshot

About

Rockwell Medical, Inc. is a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with innovative products. The company develops and commercializes specialized drug therapies for dialysis patients, including iron replacement products and hemodialysis concentrate solutions. Rockwell Medical serves the dialysis market through its proprietary technologies and product portfolio.